vero e6 cells

Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.

Amantadine (1-Aminoadamantane) is an antiviral, is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release, and blocks dopamine reuptake.

SARS-CoV-2 Mpro-IN-9 (compound c7), a nonpeptidic, noncovalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibits potent inhibitory action (IC50 = 0.085 μM) and improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. It effectively suppresses viral replication in SARS-CoV-2-infected Vero E6 cells (EC50 = 1.10 μM) and demonstrates low cytotoxicity (CC50 > 50 μM) [1].

ATV006 has antiviral activity and can be used in research on the treatment of viral infections.

SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is a conformational inhibitor of SARS-CoV-2 3CLpro with an IC50 of 0.43 μM. It demonstrates good cellular permeability, being able to effectively cross the cell membrane following co-incubation with Vero-E6 cells.

SARS-CoV-2 Mpro-IN-34 (Compound 26) acts as an inhibitor of SARS-CoV-2 Mpro with an IC50 of 6 nM. It also inhibits OC43 Mpro, demonstrating an IC50 of 33 nM. Furthermore, this compound exhibits antiviral activity in Vero E6 cells infected with SARS-CoV-2, with an EC50 of 0.103 μM.

CKP-25 is an inhibitor that disrupts the interaction between Spike RBD and ACE2, preventing virus entry into host cells, thus reducing viral replication and infection. It inhibits SARS-CoV-2 with an IC50 of 3.5 μM in Vero E6 cells.

Peptide originally derived from SARS-CoV Spike (S) protein; corresponds to amino acid residues 668 to 679. Highly potent inhibitor of SARS-CoV S protein and ACE2 interaction (IC50 = 1.88 nM in biochemical assay). Inhibits interaction of SARS-CoV S protein and Vero E6 cells in vitro. Please note, this peptide displays 80% sequence identity to homologous site on SARS-CoV-2 S-protein (residues 689-697).

MProinhibitor 11b is an inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (MPro; IC50= 0.04 μM in a TR-FRET assay).1It reduces viral yield in the culture supernatant of SARS-CoV-2-infected Vero E6 cells (EC50= 0.72 μM). MProinhibitor 11b also reduces viral RNA copy numbers in the same model when used at concentrations ranging from 1.85 to 50 μM. 1.Dai, W., Zhang, B., Jiang, X.-M., et al.Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseScience368(6497)1331-1335(2020)

SARS-CoV-2-IN-7 demonstrates potent inhibition of viral replication in SARS-CoV-2-infected Vero E6 cells with an IC50 value of 844 nM.

Niclosamide sodium (BAY2353), an orally active antihelminthic agent employed in parasitic infection research, serves as a potent STAT3 inhibitor, demonstrating an IC50 of 0.25 μM in HeLa cells. Additionally, this compound exhibits significant biological activities against cancer and effectively inhibits DNA replication in Vero E6 cells.

SARS-CoV-2-IN-54 (Compound 2), a SARS-CoV-2 inhibitor, exhibits antiviral activity in Vero E6 cells with an inhibitory concentration (IC50) of 21.4 μM [1].

SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor exhibiting antiviral activity, with an IC50 of 0.7 μM in Vero E6 cells [1].

SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active inhibitor of SARS-CoV-2 3CLpro, demonstrating potent anti-SARS-CoV-2 properties with an EC50 of 0.18 μM and exhibits minimal cytotoxicity, having a CC50 greater than 50 μM, in Vero E6 cells [1].

SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent inhibitor of SARS-CoV-2 3CLpro with an IC50 of 0.478 μM. It inhibits SARS-CoV-2 in Vero E6 cells with an EC50 of 2.499 μM and exhibits low cytotoxicity (CC50 > 200 μM) [1].

SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of SARS-CoV-2 replication, exhibiting low cytotoxicity and effectively suppressing viral replication in Vero E6 and Calu-3 cells, with half-maximal effective concentration (EC50) values of 1.99 μM and 1.92 μM, respectively [1].

SARS-CoV-2-IN-62 (Compound R3b) effectively inhibits SARS-CoV-2 replication in Vero E6 and Calu-3 cells, demonstrating low cytotoxicity with EC50 values of 2.97 μM and 3.82 μM, respectively [1].